Related Experiment Videos
Novel therapeutic options for osteoporosis
Diane M Biskobing1, Angela M Novy, Robert Downs
1Virginia Commonwealth University/Medical College of Virginia, Richmond, Virginia 23298, USA. dmbiskob@hsc.vcu.edu
Current Opinion in Rheumatology
|July 16, 2002
Summary
New osteoporosis treatments are being developed due to limitations with current therapies. Research focuses on novel agents like selective estrogen receptor modulators, bisphosphonates, and osteoprotegerin for improved efficacy and tolerability.
Area of Science:
- Bone biology and pharmacology
- Endocrinology
- Pharmacology
Background:
- Osteoporosis is a major clinical challenge, with existing treatments facing adherence issues.
- Ongoing research seeks novel therapeutic agents with improved efficacy and tolerability.
Purpose of the Study:
- To review investigational and emerging therapies for osteoporosis.
- To discuss the potential of selective estrogen receptor modulators, bisphosphonates, and other agents.
Main Methods:
- Review of current literature on osteoporosis treatments.
- Discussion of investigational agents including Arzoxifene, TSE-424, Tibolone, ibandronate, zoledronic acid, osteoprotegerin, isoflavones, and statins.
Main Results:
- Investigational agents like Arzoxifene and TSE-424 show promise in preclinical and early clinical studies.
- Tibolone is effective for bone mineral density but lacks fracture data.
- Isoflavones have shown mixed results, with recent studies questioning fracture efficacy.
- Bisphosphonates (ibandronate, zoledronic acid) offer less frequent dosing.
- Osteoprotegerin demonstrates early potential in inhibiting bone turnover.
- Statin efficacy in bone remains controversial, lacking robust clinical trial data.
Conclusions:
- Several novel therapeutic avenues are being explored for osteoporosis management.
- Further clinical trials are necessary to establish the efficacy and safety of these emerging agents, particularly concerning fracture reduction.